Lachlan Thomas, He Hejie, Aggour Hesham, Sahota Preet, Harvey Samuel, Patel Kiran, Foster Will, Yusuf Shamil, Panikker Sandeep, Dhanjal Tarv, Dandekar Uday, Barker Thomas, Parmar Jitendra, Kuehl Michael, Osman Faizel
Department of Cardiology University Hospitals Coventry & Warwickshire NHS Trust Coventry UK.
University of Warwick (Medical School) Coventry UK.
J Arrhythm. 2021 Sep 22;37(6):1522-1531. doi: 10.1002/joa3.12637. eCollection 2021 Dec.
Transvenous lead extraction (TLE) for implantable cardiac-devices is traditionally performed under general anesthesia (GA). This can lead to greater risk of exposure to COVID-19, longer recovery-times and increased procedural-costs. We report the feasibility/safety of TLE using conscious-sedation alone with immediate GA/cardiac-surgery back-up if needed.
Retrospective case-series of consecutive TLEs performed using conscious-sedation alone between March 2016 and December 2019. All were performed in the electrophysiology-laboratory using intravenous Fentanyl, Midazolam/Diazepam with a stepwise approach using locking-stylets/cutting-sheaths, including mechanical-sheaths. Baseline patient-characteristics, procedural-details and TLE outcomes (including procedure-related complications/death) were recorded.
A total of 130 leads were targeted in 54 patients, mean age ± SD 74.6 ± 11.8years, 47(87%) males; dual-chamber pacemakers (n = 26; 48%), cardiac resynchronization therapy-defibrillators (n = 17; 31%) and defibrillators (n = 8; 15%) were commonest extracted devices. Mean ± SD/median (range) lead-dwell times were 11.0 ± 8.8/8.3 (0.3-37) years, respectively. Extraction indications included systemic infection (n = 23; 43%) and lead/pulse-generator erosion (n = 27; 50%); mean 2.1 ± 2.0 leads were removed per procedure/mean procedure-time was 100 ± 54 min. Local anesthetic (LA) was used for all (mean-dose: 33 ± 8 ml 1% lidocaine), IV drug-doses used (mean ± SD) were: midazolam: 3.95 ± 2.44 mg, diazepam: 4.69 ± 0.89 mg and fentanyl: 57 ± 40 µg. Complete lead-extraction was achieved in 110 (85%) leads, partial lead-extraction (<4 cm-fragment remaining) in 5 (4%) leads. Sedation-related hypotension requiring IV fluids occurred in 2 (managed without adverse-consequences) and hypoxia requiring additional airway-management in none. No procedural deaths occurred, one patient required emergency cardiac surgery for localized ventricular perforation, nine had minor complications (transient hypotension/bradycardia/pericardial effusion not requiring intervention).
TLE undertaken using LA/conscious-sedation was safe/feasible in our series and associated with good clinical outcome/low procedural complications. Reduced risk of aerosolization of COVID-19 and quicker patient recovery/reduced anesthetic risk are potential benefits that warrant further study.
植入式心脏设备的经静脉导线拔除术(TLE)传统上在全身麻醉(GA)下进行。这可能导致更高的感染新型冠状病毒肺炎的风险、更长的恢复时间和更高的手术成本。我们报告了仅使用清醒镇静进行TLE的可行性/安全性,必要时可立即进行全身麻醉/心脏手术备用。
回顾性病例系列研究,纳入2016年3月至2019年12月期间仅使用清醒镇静进行的连续TLE病例。所有手术均在电生理实验室进行,使用静脉注射芬太尼、咪达唑仑/地西泮,并采用逐步推进的方法,使用锁定式探针/切割鞘,包括机械鞘。记录患者的基线特征、手术细节和TLE结果(包括手术相关并发症/死亡)。
共对54例患者的130根导线进行了目标拔除,平均年龄±标准差为74.6±11.8岁,男性47例(87%);最常拔除的设备为双腔起搏器(n = 26;48%)、心脏再同步化治疗除颤器(n = 17;31%)和除颤器(n = 8;15%)。平均±标准差/中位数(范围)导线植入时间分别为11.0±8.8/8.3(0.3 - 37)年。拔除指征包括全身感染(n = 23;43%)和导线/脉冲发生器侵蚀(n = 27;50%);每次手术平均拔除2.1±2.0根导线/平均手术时间为100±54分钟。所有患者均使用了局部麻醉(LA)(平均剂量:33±8 ml 1%利多卡因),静脉用药剂量(平均±标准差)为:咪达唑仑:3.95±2.44 mg,地西泮:4.69±0.89 mg,芬太尼:57±40 μg。110根(85%)导线实现了完全拔除,5根(4%)导线部分拔除(残留<4 cm片段)。2例患者出现与镇静相关的低血压,需要静脉补液(处理后无不良后果),无一例患者出现需要额外气道管理的低氧血症。未发生手术死亡,1例患者因局部心室穿孔需要紧急心脏手术,9例患者出现轻微并发症(短暂性低血压/心动过缓/心包积液,无需干预)。
在我们的系列研究中,使用LA/清醒镇静进行TLE是安全/可行的,且临床效果良好/手术并发症低。新型冠状病毒肺炎气溶胶化风险降低、患者恢复更快/麻醉风险降低是潜在益处,值得进一步研究。